Li Yongqing, Yee Cassian
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Blood. 2008 Jan 1;111(1):229-35. doi: 10.1182/blood-2007-05-089375. Epub 2007 Oct 5.
Efforts to reproducibly isolate tumor antigen-specific T cells from patients would be facilitated by removing immunoregulatory barriers. Using a human model for eliciting T-cell responses to tumor-associated antigens, we develop a novel strategy that eliminates nearly all Foxp3-expressing cells through the combination of CD25 depletion and IL-21 treatment resulting in a more than 150-fold decrease in Foxp3(+) cells to virtually undetectable levels and a more than 200-fold increase in antigen-specific cytotoxic T lymphocytes (CTLs). The extent of Foxp3 elimination and degree of expansion of antigen-specific CTLs shown in this study have not previously been achievable and are unique to IL-21. We demonstrate for the first time a possible mechanism for IL-21-mediated expansion of antigen-specific CTLs that involves suppression of Foxp3-expressing cells and reversal of inhibition to tumor-associated antigen-specific CTL generation in vitro. Taken together, the combination of CD25 depletion and IL-21 exposure, by releasing regulatory constraints, leads to markedly enhanced CTL induction and represents a robust strategy for the ex vivo generation of antigen-specific T cells for adoptive cellular therapy.
消除免疫调节障碍将有助于实现从患者体内可重复分离肿瘤抗原特异性T细胞的目标。利用一种引发T细胞对肿瘤相关抗原反应的人体模型,我们开发了一种新策略,即通过联合应用CD25清除和IL-21治疗来消除几乎所有表达Foxp3的细胞,使Foxp3(+)细胞减少超过150倍,降至几乎检测不到的水平,并使抗原特异性细胞毒性T淋巴细胞(CTL)增加超过200倍。本研究中显示的Foxp3消除程度和抗原特异性CTL的扩增程度以前是无法实现的,且是IL-21独有的。我们首次证明了IL-21介导抗原特异性CTL扩增的一种可能机制,该机制涉及抑制表达Foxp3的细胞,并在体外逆转对肿瘤相关抗原特异性CTL生成的抑制作用。综上所述,CD25清除和IL-21暴露相结合,通过解除调节限制,显著增强了CTL诱导,代表了一种强大的策略,用于体外生成抗原特异性T细胞以进行过继性细胞治疗。